| A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptorpositive/HER2-negative inoperable locally advanced or metastatic breast cancer – RIGHT Choice Study. |
Terminated |
ribociclib |
2 |
CLEE011A3201C |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A PHASE III, MULTICENTER, RANDOMISED, DOUBLEBLIND, PLACEBOCONTROLLED STUDY OF ATEZOLIZUMAB (ANTI−PDL1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER |
Completed |
ATEZOLIZUMAB / PACLITAXEL |
3 |
MO39196 |
IMC (Closed), KFSH (Closed), KFMC (Closed) |
| AN OPEN LABEL, SINGLE ARM, MULTICENTER,SAFETY STUDY OF ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL OR NON-UROTHELIAL CARCINOMA OF THE URINARY TRACT |
Completed |
Atezolizumab (MPDL3280A; RO5541267) |
3 |
MO29983 |
KFSH & RC-R |
| Low INR to Minimize bleeding with mechanical valves Trial (LIMIT) |
Ongoing |
WARFARIN SODIUM |
3 |
2231351 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Randomized, Single Oral Dose, Open Label, Two Sequence, Two Treatment, Four Periods, Full Replicate Crossover Study to Determine the Bioequivalence of Azacitidine 300 mg Film Coated Tablets Versus Onureg® 300 mg Film Coated Tablets For Adult Patients with Acute Myeloid Leukaemia (AML) under Fasting Conditions |
Ongoing |
Azacitidine 300 mg Film- Coated Tablets |
BE |
HIK-AZA-2023-01 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam) |
| A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects with Transfusion-Dependent β-Thalassemia or Severe Sickle Cell Disease |
Ongoing |
Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) |
3 |
VX21-CTX001-161 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight related complications or risk factors for CVD |
Ongoing |
BI 456906 |
3 |
1404-0040 |
King Faisal Specialist Hospital and Research Center (Riyadh) , King Fahad Specialist Hospital (Dammam), King Abdulaziz University Hospital (Jeddah),King Saud Medical City (Riyadh) |
| Stroke and High-risk TIAs Outcomes with Reduction of Treatment duration in Emergency Rooms. (SHORTER-Study). |
Ongoing |
PLAVIX Clopidogrel 75 MG TABLET |
3 |
1 |
King Faisal Specialist Hospital and Research Center (Riyadh),King Fahad Medical City (Riyadh),King Faisal Specialist Hospital and Research Center (Jeddah) |
| Open-label, long-term safety and efficacy study of Mim8 in participants with haemophilia A with or without inhibitors |
Ongoing |
NNC0365-3769 B (Mim8) |
3 |
NN7769-4532 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Prospective Observational study to describe the pattern and effectiveness of the utilization of different treatment options for Metastatic Renal Cell Carcinoma (OPERA) |
Ongoing |
Tyrosine Kinase inhibitors and Immunotherapy |
4 |
OPERA2020 |
King Faisal Specialist Hospital and Research Center (Jeddah) |
